Molecular Testing of Lung Cancers.
- Author:
Hyo Sup SHIM
1
;
Yoon La CHOI
;
Lucia KIM
;
Sunhee CHANG
;
Wan Seop KIM
;
Mee Sook ROH
;
Tae Jung KIM
;
Seung Yeon HA
;
Jin Haeng CHUNG
;
Se Jin JANG
;
Geon Kook LEE
Author Information
- Publication Type:Review
- Keywords: Lung neoplasms; Molecular testing; Guideline; Precision medicine
- MeSH: Biomarkers; Gene Rearrangement; Humans; Lung Neoplasms*; Lung*; Lymphoma; Pathology, Molecular; Phosphotransferases; Precision Medicine; Protein-Tyrosine Kinases; Receptor, Epidermal Growth Factor
- From:Journal of Pathology and Translational Medicine 2017;51(3):242-254
- CountryRepublic of Korea
- Language:English
- Abstract: Targeted therapies guided by molecular diagnostics have become a standard treatment of lung cancer. Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are currently used as the best predictive biomarkers for EGFR tyrosine kinase inhibitors and ALK inhibitors, respectively. Besides EGFR and ALK, the list of druggable genetic alterations has been growing, including ROS1 rearrangements, RET rearrangements, and MET alterations. In this situation, pathologists should carefully manage clinical samples for molecular testing and should do their best to quickly and accurately identify patients who will benefit from precision therapeutics. Here, we grouped molecular biomarkers of lung cancers into three categories—mutations, gene rearrangements, and amplifications—and propose expanded guidelines on molecular testing of lung cancers.
